See the DrugPatentWatch profile for Simulect
What patents cover “Simulect” in bioprocessing—where that name shows up
“Simulect” is a brand name for basiliximab (an anti-IL-2 receptor monoclonal antibody used as an immunosuppressant in transplant settings). Patent records under the terms “Simulect” and “basiliximab” commonly fall into several buckets: antibody discovery/sequence and binding properties, production and formulation, and later process and manufacturing improvements (including bioprocess steps used to make the drug substance and drug product) [1].
Because “Simulect bioprocess patents” can be interpreted two ways (patents about making basiliximab vs. patents owned by the Simulect product parties), the relevant patents typically come from the basiliximab development/manufacturing patent families rather than from a single “bioprocess only” document.
Which companies and patent owners typically appear in basiliximab manufacturing/process filings
Most of the long-running basiliximab patent landscape is tied to the original developers and their manufacturing/formulation teams, followed by later assignees who file process improvements and analytics/quality-system-related manufacturing patents as technology evolves [1]. If you run a patent search, the assignee name matters as much as the product name, because “Simulect” may appear in some documents even when the invention is framed around “basiliximab” or “anti-IL-2 receptor antibody” rather than the brand.
How to search for “bioprocess” patents specifically (not just composition-of-matter)
To find manufacturing and process claims for a biologic like basiliximab, search with combinations that target process/manufacturing language rather than only the antibody itself. Useful search strings include:
- “basiliximab” AND “process for producing”
- “basiliximab” AND (chromatography OR “protein A” OR “ion exchange” OR “tangential flow” OR TFF)
- “basiliximab” AND (refolding OR “cell culture” OR harvest OR clarification)
- “basiliximab” AND (viral inactivation OR “low pH” OR nanofiltration)
- “basiliximab” AND (“formulation” OR “stabilizer” OR “buffer” OR “lyophilized”)
- “basiliximab” AND (“sterile filtration” OR “fill-finish” OR “sterilizing filter”)
In practice, brand mentions (“Simulect”) can be sparse in later process-optimization patents, so filtering by basiliximab and process terms usually performs better than relying on the brand string alone [1].
What kinds of bioprocess inventions show up for monoclonal antibodies like basiliximab
Bioprocess-related patent claim themes for antibodies typically include downstream purification and safety steps, such as:
- cell culture and harvest conditions (upstream)
- purification workflows and chromatography resins/steps (downstream)
- viral clearance mechanisms (e.g., dedicated inactivation steps and/or membrane filtration)
- formulation and storage conditions that protect potency and stability
- scale-up or hold-time improvements that reduce aggregation or loss of activity
These categories commonly appear in basiliximab-related patent families once the program matures from development into commercial manufacturing [1].
How long these patents can last—and why multiple patent types matter for “bioprocess” freedom to operate
Even if the core antibody composition patents have long since expired or neared expiry, manufacturing and formulation patents can remain relevant longer, and additional “improvement” patents can extend operational constraints. Also, for biologics, there can be a patchwork across jurisdictions: some patents expire earlier, and some process-related patents can remain in force in specific countries depending on filing dates and term calculations [1].
If your goal is freedom to operate for an internal or contract manufacturing process, you generally need to map:
1) drug substance process steps,
2) drug product fill-finish steps,
3) viral safety strategy,
4) specific formulation components and parameters,
5) claimed analytics/release testing steps (sometimes relevant),
then compare them against active claims in each target jurisdiction [1].
If you meant “Simulect” as in biosimilar manufacturing: what to check
If you’re looking at biosimilar or alternative-manufacturer routes, “Simulect bioprocess patents” usually translates into: which claims could be infringed by a generic/biosimilar manufacturing scheme. The key practical approach is claim-by-claim comparison of your intended process against the specific active process claims in the relevant patent family members in the countries of interest [1].
Patent search sources you can use right away
A reliable way to assemble the relevant patent set is to start with a basiliximab/Simulect keyword search in major patent databases, then expand by:
- assignee (owner) links,
- CPC/IPC codes tied to antibody production and purification,
- citation networks (patents that cite early basiliximab filings and those cited by process patents) [1].
What I need from you to pull the exact “Simulect bioprocess” patent list
If you tell me the following, I can narrow the patent families to the most relevant process claims:
- Country/jurisdictions (e.g., US, EP, JP, IN)
- Whether you want “drug substance” process patents, “drug product” (formulation/fill-finish), or both
- Whether you want original assignees only or also later process-improvement assignees
- Your target technology focus (e.g., purification train, viral clearance, formulation, or TFF/UF)
Sources
[1] https://worldwide.espacenet.com/